Back to top
more

Asensus Surgical (ASXC)

(Real Time Quote from BATS)

$0.25 USD

0.25
235,994

0.00 (0.00%)

Updated Apr 30, 2024 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 46% (136 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company???s transformational plans continue to benefit its operating income.

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Down -25.24% in 4 Weeks, Here's Why Asensus Surgical (ASXC) Looks Ripe for a Turnaround

by Zacks Equity Research

Asensus Surgical (ASXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Cardinal Health (CAH) and Asensus Surgical (ASXC) have performed compared to their sector so far this year.

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

by Zacks Equity Research

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Thermo Fisher Scientific (TMO) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.97% and 0.04%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) Q3 Earnings Lag Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of -23.65% and 3.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line

by Zacks Equity Research

Asensus Surgical (ASXC) reports a significant increase in total surgical procedures completed utilizing the Senhance System.

Asensus Surgical (ASXC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of -12.50% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of -28.57% and 18.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 13.33% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 25.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Q3 Earnings Lag Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of -3.85% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 8.57% and 8.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Industry Outlook Highlights ShockWave Medical, Semler Scientific and Asensus Surgical

by Zacks Equity Research

ShockWave Medical, Semler Scientific and Asensus Surgical are part of Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on R&D investments. SWAV, SMLR and ASXC are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is disrupting the trend.

Asensus Surgical (ASXC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 12.50% and 20.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 12.50% and 4.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 12.50% and 18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -35.48% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 4.76% and 0.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?